Only in Titles

Search results for: Mouse Anti-Human C4d Antibodies

paperclip

#25058376   // To Up

Deciphering complement interference in anti-human leukocyte antigen antibody detection with flow beads assays.

Anti-human leukocyte antigen (HLA) antibody detection in solid-phase flow beads assays can be quenched by complement activation, but the precise mechanism of this interference is not fully elucidated yet.
Jonathan Visentin, Margaux Vigata, Sophie Daburon, Cécile Contin-Bordes, Véronique Fremeaux-Bacchi, Claire Dromer, Marc-Alain Billes, Martine Neau-Cransac, Gwendaline Guidicelli, Jean-Luc Taupin

1306 related Products with: Deciphering complement interference in anti-human leukocyte antigen antibody detection with flow beads assays.

100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100 μg

Related Pathways

paperclip

#22759336   2012/07/03 To Up

Patterns of de novo allo B cells and antibody formation in chronic cardiac allograft rejection after alemtuzumab treatment.

Even though the etiology of chronic rejection (CR) is multifactorial, donor specific antibody (DSA) is considered to have a causal effect on CR development. Currently the antibody-mediated mechanisms during CR are poorly understood due to lack of proper animal models and tools. In a clinical setting, we previously demonstrated that induction therapy by lymphocyte depletion, using alemtuzumab (anti-human CD52), is associated with an increased incidence of serum alloantibody, C4d deposition and antibody-mediated rejection in human patients. In this study, the effects of T cell depletion in the development of antibody-mediated rejection were examined using human CD52 transgenic (CD52Tg) mice treated with alemtuzumab. Fully mismatched cardiac allografts were transplanted into alemtuzumab treated CD52Tg mice and showed no acute rejection while untreated recipients acutely rejected their grafts. However, approximately half of long-term recipients showed increased degree of vasculopathy, fibrosis and perivascular C3d depositions at posttransplant day 100. The development of CR correlated with DSA and C3d deposition in the graft. Using novel tracking tools to monitor donor-specific B cells, alloreactive B cells were shown to increase in accordance with DSA detection. The current animal model could provide a means of testing strategies to understand mechanisms and developing therapeutic approaches to prevent chronic rejection.
J Kwun, B C Oh, A C Gibby, R Ruhil, V T Lu, D W Kim, E K Page, O P Bulut, M Q Song, A B Farris, A D Kirk, S J Knechtle, N N Iwakoshi

1254 related Products with: Patterns of de novo allo B cells and antibody formation in chronic cardiac allograft rejection after alemtuzumab treatment.

50 UG100ug Lyophilized100ug100ug100ug0.1 mg100ug100ug Lyophilized

Related Pathways